Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.44 |
| ▸ | BRAF | P15056 | 9/20 | 0.42 |
| ▸ | RAF1 | P04049 | 8/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | CIT | O14578 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | MUSK | O15146 | 1/20 | 0.41 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | PDE6D | O43924 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | STK10 | O94804 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2248112 | 0.88 | KDR (0.43) | KDRBRAFRAF1MAPK14EPHX2 | |
| SCHEMBL2246305 | 0.85 | RAF1 (0.43) | KDRBRAFRAF1MAPK14P2RX3 | |
| SCHEMBL2246431 | 0.85 | KDR (0.42) | KDRBRAFRAF1MAPK14P2RX3 | |
| SCHEMBL2246329 | 0.81 | RAF1 (0.37) | KDRBRAFRAF1MAPK14P2RX3 | |
| SCHEMBL2243427 | 0.80 | BRAF (0.44) | KDRBRAFRAF1MAPK14EPHX2 | |
| SCHEMBL177543 | 0.80 | KDR (0.60) | KDRBRAFRAF1MAPK14EPHX2 | |
| SCHEMBL2249935 | 0.79 | ABL1 (0.43) | KDRBRAFRAF1MAPK14EPHX2 | |
| SCHEMBL2244687 | 0.78 | MAPK14 (0.63) | KDRBRAFRAF1MAPK14EPHX2 | |
| SCHEMBL2243539 | 0.78 | BRAF (0.44) | KDRBRAFRAF1MAPK14P2RX3 | |
| SCHEMBL2243151 | 0.78 | MET (0.40) | KDRBRAFRAF1MAPK14P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | UMPS, SLC14A1, CPS1 | KDR 4185/4885BRAF 338/4885RAF1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.